Posted by Michael Wonder on 27 Nov 2021
Ono receives approval of Opdivo (nivolumab) for expanded use for two indications in Japan
25 November 2021 - Ono Pharmaceutical and Bristol-Myers Squibb today announced that Ono has received the approvals of Opdivo (nivolumab) for expanded use for the first-line treatment of unresectable advanced or recurrent gastric cancer in combination with chemotherapy, and adjuvant treatment of oesophageal cancer, for a partial change in approved items of the manufacturing and marketing approval.
This approval is based on the results from 2 clinical trials: CheckMate-649 (ONO-4538-44) and ATTRACTION-4 (ONO-4538-37).
